Medizone International, Inc. (OTCMKTS:MZEI) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
press release announcing the appointment of Mr. Brad Goble as a
consultant to the Company on bio-terrorism matters. A of the
press release is attached as Exhibit 99.1 to this Current Report
on Form 8-K. The information in this Item 7.01 and Exhibit 99.1
attached hereto shall not be deemed filed for purposes of Section
18 of the Exchange Act, or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference
in any filing under the Securities Act of 1933, as amended, or
the Exchange Act, except as expressly set forth by specific
reference in such filing.
|
Exhibit Number
|
Description
|
|
|
99.1
|
Press Release dated May 30, 2017.
|
About Medizone International, Inc. (OTCMKTS:MZEI)
Medizone International, Inc. is engaged in designing, manufacturing and selling a system using ozone in the disinfection of surgical and other medical treatment facilities and in other applications. The Company’s AsepticSure is an ozone-based technology, which is used for the purpose of decontaminating and disinfecting hospital surgical suites, emergency rooms, intensive care units and other enclosed spaces, such as gym locker rooms, laboratories and veterinary clinics. In the AsepticSure system, oxygen atoms are misted into the environment with a hydrogen peroxide vapor and the system’s formula creates Trioxidane. The Company is developing a variant of AsepticSure for governmental use with bio-terrorism countermeasures. AsepticSure has completed safety and preliminary operational trials. During the tests, AsepticSure has demonstrated a turnaround time of approximately 90 minutes for disinfection and reoccupation of the hospital rooms. Medizone International, Inc. (OTCMKTS:MZEI) Recent Trading Information
Medizone International, Inc. (OTCMKTS:MZEI) closed its last trading session down -0.0005 at 0.0695 with shares trading hands.
